Search
Neisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen
go.drugbank.com/drugs/DB10801ApprovedInvestigationalNeisseria meningitidis group w-135 capsular polysaccharide diphtheria toxoid conjugate antigen is an active intramuscular immunization for the prophylaxis of invasive meningococcal disease caused by *Neisseria … The vaccine contains *N. meningitis* serogroup W-135 capsular polysaccharide antigens that are purified and individually conjugated to diphtheria toxoid protein that are extracted from *Corynebacterium
Nedosiran
go.drugbank.com/drugs/DB17635ApprovedInvestigationalNedosiran is an RNA interference targeting hepatic lactate dehydrogenase, the enzyme responsible for the conversion of glyoxylate to oxalate. … This approval is based on the favorable results from the pivotal phase 2 PHYOX<sup>TM</sup>2 and interim data from the ongoing phase 3 PHYOX<sup>TM</sup>3 clinical trials.[L48325]
Isosorbide
go.drugbank.com/drugs/DB09401ApprovedInvestigationalIsosorbide was previously available in an oral formulation for the reduction of intraocular pressure. It was approved by the FDA in 1980, but has since been discontinued. … Refer to these drug entries for more information.
Iobenguane sulfate I-123
go.drugbank.com/drugs/DB09546ApprovedIobenguane sulfate I-123 is a radiopharmaceutical used in gamma-scintigraphy of adrenergically inervated tissues [FDA Label].
Pinaverium
go.drugbank.com/drugs/DB09090ApprovedInvestigationalPinaverium is a spasmolytic agent used for functional gastrointestinal disorders. It is a quaternary ammonium compound that acts as an atypical calcium antagonist to restore normal bowel function. … Although it is not a currently approved drug by the FDA, pinaverium is available in over 60 countries including Canada.
Categories: Drugs for Functional Gastrointestinal DisordersAmlexanox
go.drugbank.com/drugs/DB01025ApprovedWithdrawnAmlexanox is an antiallergic drug, clinically effective for atopic diseases, especially allergic asthma and rhinitis.
Categories: Drugs for Obstructive Airway DiseasesSparsentan
go.drugbank.com/drugs/DB12548ApprovedInvestigational[L45300] On April 24, 2024, sparsentan was granted conditional marketing authorization by the European Commission for the treatment of adults with primary IgAN.[L51559] … >A</sub>R and 0.8 nM for AT<sub>1</sub>R).
Alendronic acid
go.drugbank.com/drugs/DB00630ApprovedInvestigationalAlendronic acid is a second generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease[FDA Label][A959,A203111]. … It functions by preventing resorption of bone[FDA Label][A959].
Categories: Drugs for Treatment of Bone DiseasesCeliprolol
go.drugbank.com/drugs/DB04846ApprovedInvestigationalWithdrawnCeliprolol is not approved for use by the FDA in the treatment of vascular Ehlers–Danlos syndrome. … Celiprolol is indicated for the management of mild to moderate hypertension and effort-induced angina pectoris.
Armodafinil
go.drugbank.com/drugs/DB06413ApprovedInvestigationalArmodafinil is produced by the pharmaceutical company Cephalon Inc. (a wholly owned subsidiary of Teva Pharmaceutical Industries Ltd.) and was approved by the U.S. … of the wakefulness-promoting agent modafinil (Provigil), and is indicated to improve wakefulness in adult patients with excessive sleepiness associated with obstructive sleep apnea (OSA), narcolepsy, or
Categories: Psychostimulants, Agents Used for ADHD and Nootropics